Journal of Biomedical and Pharmaceutical Research
Available Online at www.jbpr.in
CODEN: - JBPRAU (Source: - American Chemical Society)
NLM (National Library of Medicine): ID: (101671502)
Index Copernicus Value 2020: 76.36
Volume 11, Issue 5, September-October: 2022, 62-73

ISSN (Online): 2279-0594
ISSN (Print): 2589-8752

Original Research Article

Immunotherapy in Cancer: Biology Therapy

Monika D. Khichade[1]*, Dr .Sameer Shafi[2], Priyanka S. Nilangekar[3], Aishwarya S. Gandhle[4], Mohini A . Gurav[5,] Vishal B. Phulsundar [6]

[1,3,5,6] Student, Shivlingeshwar College of Pharmacy Almala , Latur , (M.S) India.

[2] Head of Department (Pharmaceutics) Shivlingeshwar College of Pharmacy, Almala ,Tq. Ausa, Dist .Latur (M.S) India.

[4]Student, NIPER Hydrabad, India.

Article Info: Received 08 September 2022; Accepted 1 October 2022
DOI: https://doi.org/10.32553/jbpr.v11i5.937
Address for Correspondence: Monika D. Khichade
Conflict of interest statement: No conflict of interest

Abstract:
The relationship between immune system and cancer has progressively increased in the last few years. Recent advancement in treating cancer immunotherapy includes monoclonal antibodies, adaptive cancer therapy; monoclonal antibodies have came into force. General therapies include surgery, radiation and chemotherapy etc... Beyond that the immunotherapy in treating cancer helps our immune system to fight against tumor forming cell, which acts as an example of precision medicine .It mainly targets tumor in filtering lymphocytes, CAR Tcells, TCR Tcell etc…. Personalized combination therapy stands as promising stratergy for upcoming cancer treatment, personalized medicines includes patient derived tumor cell DNA oncolytic viruses dendritic cells etc.
Key Words: cancer, immunotherapy, checkpoint inhibitor, nanomedicine

Introduction

Cancer may be a complicated sickness characterised by uncontrolled growth of cells and enlargement of those abnormal cells within the body, that caused over nine.6 million deaths worldwide in 2017 alone [1]. relating to the estimation of yank Cancer Society for 2021, specialists take into account that almost one.9 million individuals are diagnosed with cancer and virtually 608,570 individuals can die from cancer [2]. The cancer-related mortality within the world is anticipated to succeed in twenty two million by the year 2030.

Among the assorted approaches used in cancer treatment, surgery is typically the primary treatment of alternative. The acceptable strategy for treatment is developed per the sort and stage of cancer. alternative treatment strategies in clinical follow area unit therapy and radiation and mixtures of those approaches. Therapy mistreatment varied antineoplastic agents may be applied as initial line treatment for therapeutic functions, however conjointly to forestall the proliferation of cancer cells once surgery or radiation or to scale back the dimensions of tumour tissue before surgery.

Today, though it's doable to treat cancer with one treatment methodology alone or with a mixture of various treatment strategies, the specified success rate in cancer treatment has not nonetheless been achieved. The most reason for this failure is that the general toxicity and unsought facet effects caused by the treatment strategy, notably for therapy. so as to beat these facet effects and supply simpler cancer treatment with lower doses of active ingredient, completely different treatment ways are developed. Therapy, that has attracted attention in recent years, may be outlined because the use of system options in cancer treatment [3]. In alternative words, therapy is outlined as a kind of biotherapy and relies on the sensitization of the patient's system to cancer that will increase property and reduces facet effects [4]. The prevalence of cancer therapy in clinical trials light-emitting diode to the choice of cancer therapy because the "2013 Breakthrough of the Year" by Science [5]. As with different treatment strategies, therapy is subject to some limitations as a result of it should impair immune physiological state by inflicting associate degree immune response that ought to not use against traditional tissue. as an example, inflammation, redness and itchiness will be determined oft looking on indefinite quantity of medication and private factors [6]. However, positive results are obtained in therapy studies that concentrate on minimum aspect effects compared to traditional treatments. Therefore, the advances and improvement in therapy through technology and nanoparticulate delivery systems might have a positive impact on treatment success.

The Immune System And Its Role In Cancer Immunotherapy

The system consists of innate and adjustive immune parts (Table 1). The innate arm is that the 1st defense against the matter and is chargeable for generating abrupt and passing responses with monocytes, macrophages, nerve fiber cells and natural killer cells. Innate system cells area unit accountable of recognition of non-host cells and also the presenting of cells of matter nature to adjustive system cells. Innate system cells have receptors to acknowledge microorganisms, broken cellsand remodeled cells,i.e., growth cellOn theopposite hand,the adjustive armproduces durable responses exploitation T cells and B cells, eventually generating immune memory [7]. adjustive immunity is predicated on T and B-lymphocytes that proliferate once recognition and destroy matter structures by stimulating varied mechanisms.Besidesthesecells,theimmunesystem'sconstituents embrace cytokines, antibodies, plasma and adhesion molecules, tissues and organs like the thymus, bone marrow and spleen [8].

Table 1: Immune system types and constituents.

Innate Immunity	Adoptive Immunity
Epithelial barriers	B Lymphocytes
Phagocytes (Macrophage ex.)	T Lymphocytes
Mast cells	
Dendritic cells	
Natural killer and other innate lymphoid cells	

Stratergies In Cancer Immunotherapy

The effectivity of cancer therapy has been incontestable by clinical studies similarly as in vitro and in vivo studies [9]. There are a unit many alternative therapy medicine approved by the Food and Drug Administration (FDA) to be employed in cancer medical aid: recombinant-human-IL-2 for urinary organ neoplastic cell therapy; 1st antibody for B-cell malignancies; 1st DC-based cancer immunogenic for

adenocarcinoma therapy; mythical monster substance receptor (CAR)-engineered cell therapy for B-cell lymphoma; and programmed death ligand-1 (PD-L1) immune stop blockers for malignant melanoma area unit samples of immunotherapeutics approved to be used within the treatment of cancer within the last thirty years [10]. The evaluations of over forty antibodies in cancer area unit continued in late-stage clinical studies. On the opposite hand, immunotherapeutic administered together medical aid are often thought-about an affordable and effective thanks to treat cancer [11]. The government agency and European Medicines Agency (EMA) approved 2 vaccines—T-VEC (Imylgic®) to induce DC production in malignant melanoma and Sipuleucel-T (Provenge®) to provide genes expressing granulocyte-macrophage colony-stimulating issue (GM-CSF)in pathologic process adenocarcinoma, severally [12]. over eighty antibody-based product area unit already approved by the government agency and EMA [13]. what is more, ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, cemiplimab and avelumab area unit immune stop inhibitors (ICIs) approved by the government agency and approved by the EMA within the last seven years [14]. For unresectable or pathologic process malignant hepatoma, atezolizumab and bevacizumab area unit approved as combined medical aid by the government agency in 2020 [15]. Meanwhile, the government agency has promoted completely different combos of therapy, like ipilimumab and T-VEC, pembrolizumab and T-VEC, ipilimumab and amide immunogen, nivolumab and amide immunogen and pembrolizumab and microorganism immunogen in malignant melanoma, and ipilimumab and Sipuleucel-T in adenocarcinoma [16].Cancer immunotherapy strategies are basically divided into four types (Figure .1): immunomodulation, adoptive cellular therapy, targeted antibodies and cancer vaccines



Figure 1: Immunotherapy approaches for cancer treatment

Immunomodulation:

Focuses on rising the immune reaction by priming the host system. Though totally different agents play a job in immunomodulation, the fundamental approach relies on the stimulation of matter presenting cells to T cells and consequently the more killing of neoplasm cells by T cells. Cytokines are the leading immunomodulation agents. There are many cytokine-based immunomodulators approved to be used in therapy of various cancer sorts. as an example, Aldesleukin (Proleukin®) may be a artificial style of IL-2 made by deoxyribonucleic acid technology and is approved for the treatment of excretory organ cancer and malignant melanoma [17]. Another example is antiviral drug alfa-2b (Intron A®), additionally made by

recombinant technology and utilized in the treatment of malignant neoplastic disease, malignant neoplastic disease and malignant melanoma [18].Another immunomodulators cluster utilized in cancer therapy are stop inhibitors. stop inhibitors act by block the proteins that stop the system from assaultive cancer cells. in step with their mechanism of action, they will even be outlined as targeted medical aid, as a result of stop inhibitors inhibit specific proteins on the T lymphocyte or neoplastic cell. as an example, Ipilimumab (Yervoy®), developed to inhibit CTLA-4 (cytotoxic lymphocyte associated supermolecule 4) expressed on T cells, is employed within the treatment of advanced malignant melanoma. Normally, CTLA-4 may be a supermolecule receptor that acts as associate immune stop that down regulates immune responses. during this means, it prevents the system from assaultive healthy cells in reaction diseases like atrophic arthritis and colitis. However, within the treatment of malignant melanoma, the aim is to extend the attack of T cells to the neoplasm by inhibiting this CTLA-4 receptor [19]. PD-L1 is one among the cell surface proteins expressed on cancer cells that functions as associate system suppressor. Atezolizumab (Tecentriq®), developed as a PD-L1 matter, is employed within the treatment of carcinoma and urothelial cancer [20]. Though a restricted patient cluster edges from immune stop blockers with on the brink of four-hundredth response rates within the clinics, the impact depends on the T lymphocyte levels at the neoplasm web site. For this reason, these agents are combined with other chemotherapeutics, radiotherapeutics or vaccines. additionally, recent studies have shown that some chemotherapeutical agents, like antibiotic drug, have elicited host system once used alone or combined with therapy. Moreover, the analysis on the efficaciousness of antibiotic drug and immune stop blockers is in progress in clinical trials (NCT04028063). it's well-known that antibiotic drug will induce growth lymphocyte responses that induce immunogenic death by cathartic calreticulin (CRT) and high quality cluster box one (HMGB1) [10,21] during a study, αPD-L1 and αCTLA-4 antibodies combined with IL-2 in collagen-binding domain (CBD). neoplasm volume was reduced within the malignant melanoma, colon, and breast neoplasm models within the CBD-IL2-treated cluster. However, once CBD-ICI and CBD-IL2 were administered along, it had been emphasised that the neoplasm was virtually fully destroyed within the breast neoplasm model and a survival rate of sixty nine was achieved when one hundred days [22]. In another study CBD combined with the chemokine CCL4 and its effectiveness was evaluated in multiple neoplasm models. Additionally to hyperbolic neoplasm accumulation, overexpress of DC and T cells was been rumored [23]. IL-12 was combined with CDB to attenuate its adverse effects and its efficaciousness was evaluated when blood vessel administration during a malignant melanoma model. As a results of the study, it had been rumored that IFN-y, EL and AST levels were attenuated compared to free IL-12. Whereas short neoplasm shrinkage was discovered once IL-12 was administered alone, a long-run antitumoral response of nearly hour was obtained once IL-12and ICI were administered together [24]. Additionally, clinical trials square measure in progress on new immune stop inhibitors. for instance, success within the treatment of solid tumors is discovered in phase I studies with antibodies targeted to CD47, CD73, A2Ar and TIM-3 [25].

Targeted Antibodies: being associatetibodies (mAbs) will be concisely outlined as antibodies that bind to specific elements of a matter. The high specificity of being antibodies binding to cancer cells has created it inevitable that it might be employed in cancer treatment. mAbs are researched to be used in cancer treatment for several years and there area unit a spread of merchandise on the market. the thought of making the most of active targeting in cancer treatment has created the utilization of mAbs inevitable. Especially, the invention of tumor-

specific antigens has enlarged the interest in mAbs. the most reason for victimisation mAbs in therapy is that general toxicity will be prevented. For this reason, versatile analysis continues for the utilization of mAbs in cancer treatment. Rituximab, developed for CD20 expressed on the surface of B cells in non-Hodgkin malignant neoplastic disease, is that the initial mAb employed in cancer treatment. Afterwards, anti-HER2 Trastuzumab for carcinoma treatment and anti-VEGF Bevacizumab and anti-EGFR Cetuximab for body part cancer treatment were approved. To date, around thirty mAbs area unit FDA-approved to be used in cancer treatment and area unit on the market [26,27]. mAbs will be used alone in cancer treatment or together with antitumor agents. This technological approach, referred to as antibody–drug conjugate, aims to hold antitumor|malignant neoplasm|metastatic tumor} medicine to the tumor via mAbs created specifically on the neoplastic cell surface matter. during this approach, a variety of therapy with enlarged potency and reduced aspect effects is provided [28]. Kadcyla is associate antibody–drug conjugate approved by the bureau and EMA in 2013 to be used within the treatment of HER2-positive pathologic process carcinoma [29]. it's a mixture of anti-HER2 Trastuzumab and DM1, a therapy drug effective on microtubules. Adcetris may be a conjugation of Brentuximab (chimeric IgG1) that targets CD30 on the neoplastic cell surface and therefore the cytotoxic agent monomethyl auristatin E. it had been approved by the bureau in 2011 and so by the EMA in 2012 to be used within the treatment of Hodgkin malignant neoplastic disease [30].

Adoptive Cell Medical Aid:

Is a kind of therapy applied to assist the system fight cancer cells. In cellular therapy, T cells square measure employed in other ways by taking advantage of their natural skills to eliminate cancer cells . Basically, T cells square measure collected from the cancer patient's blood or neoplasm tissue and so modified within the laboratory to higher target the cancer cells and so given to the patient [31]. The presence of T cells might not continually be enough to eliminate cancer cells. Killer T cells should even be gift in a very enough variety of neoplasm sites, be pre-activated and maintain their activity till the neoplasm is totally eliminated. Tumor-Infiltrating leucocyte (TIL) medical aid, one in every of the adoptive cell medical aid applications, is associate immonutherapy approach that aims to provides all of those conditions. In TIL treatment, T cells that have already infiltrated the neoplasm tissue of the patient with cancer square measure collected, swollen and re-infused into the patient so as to supply a enough variety. Despite the promising edges of TIL medical aid, it's some limitations. sadly, though T cells square measure reproduced in vitro conditions, generally enough numbers square measure still not achieved in patients. to beat this issues, built lymph cell receptor (TCR) medical aid mistreatment peripheral lymphocytes has been developed with associate recombinant DNA technology approach. This approach not solely activates and expands existing anti-tumor T cells, however additionally allows the T cells to focus on specific cancer antigens. In each TIL and TCR treatment approaches, solely cancer cells presenting their antigens will be targeted. T cells will acknowledge cancer because of the MHC-mediated presentation of specific antigens expressed on the surface of cancer cells. within the chimeral matter receptor (CAR-T) approach developed to beat this limitation, T cells acknowledge cancer cells as MHC-independent. This approach is associate example of customized medication observe {and the|and therefore the|and additionally the} Food and Drug Administration and EMA have also approved CAR-T therapeutic product Kymriah® and Yescarta® to be used in cancer treatment [32].

Vaccine:

Use in cancer therapy is associate degree example of active therapy. In active therapy, the aim is to activate the effector functions of the system [33]. the most purpose of cancer

vaccines containing growth cells or antigens is to stimulate the system, destroy the growth and forestall relapse. Cancer vaccines area unit answerable for introducing specific antigens expressed on the surface of cancer cells to the system. With the elucidation of the structures of neoplastic cell specific tumor-associated antigens, interest in cancer vaccines is increasing day by day. These antigens area unit combined with adjuvants and accustomed activate the system against cancer. Cancer vaccines area unit developed to forestall or treat cancer. as an example, there area unit vaccines for human papillomavirus (HPV), that is related to differing kinds of cancer like cervical, duct and throat is finished to forestall cancer. Similarly, the hepatitis B (HBV) virus may be accustomed cut back the danger of carcinoma in patients with chronic disease. In cancer vaccines developed for therapeutic functions, adjuvants that facilitate increase the immunologic response area unit typically used. Sipuleucel-T (Provenge), the primary commercially offered cancer vaccinum, could be a nerve fiber cell-based vaccinum developed for the treatment of hormone-refractory glandular cancer [34]. Talimogene laherparepvec (T-VEC) could be a vaccinum utilized in the treatment of skin cancer associate degreed is an oncolytic herpes simplex virus developed with a gene-splicing approach. it's additionally the primary FDA-approved oncolytic microorganism medical care product [35,36].

Mechanism of Action of Checkpoint Inhibitors (Icis) :

Although cancer cells are shaped daily, the majority of them are properly eliminated through the host immune response. Immune responses to cancer cells are referred to as cancer-immunity cycles and comprise seven phases: (1) unleash of cancer antigens by the death of cancer cells, (2) presentation of cancer antigens to T cells by antigen-presenting cells like nerve fiber cells, (3) lymph cell activation (priming phase), (4) lymph cell migration, (5) lymph cell infiltration, (6) neoplastic cell recognition, and (7) attack and elimination of cancer cells (effector phase) [37]. However, cancer cells with low immunogenicity,which don't gift cancer antigens, could evade this response response and survive for a extended length (equilibrium phase) [37,38,]. Further, immunological disorder mechanisms activated upon the buildup of mutations in cancer cells, the induction of restrictive T cells (Tregs) and immunological disorder cells together with myeloid-derived suppressor cells (MDSCs), and also the expression of immune stop molecules like PD-L1 end in uncontrolled tumour growth (escape phase)[37,38]. Thus, sure cancers are detected solely when the cancer cells approach the escape part and endure uncontrolled proliferation, having already established a system preventing them from being eliminated through the response response. ICIs are medicine that block the immunological disorder mechanisms of cancer cells (Figure 2). ICIs exert their growth effects by harnessing host response functions, as opposed to cytocidal anticancer medicine, that inhibit the cell cycle, and agents that directly attack cancer cells, like molecularly targeted medicine that specifically bind to mutation sites and suppress proliferative signals. Currently, anti-PD-1/PD-L1 antibodies ar clinically used to treat carcinoma and numerous different cancers. In carcinoma, PD-L1 expression is employed together of the biomarkers to tell apart the treatment indication cases. Microsatellite instability has additionally been used as a possible anti-PD-1/PD-L1 antibodies treatment biomarker in internal organ cancer, primarily as a second-line treatment when normal treatment, in triple-negative carcinoma, and as a biomarker candidate in body part cancer. In 2011, monotherapy with ipilimumab, Associate in Nursing anticytotoxic T-lymphocyte substance four (CTLA-4) protein, was approved by the food and drug administration (FDA) for advanced-stage melanoma, and in 2015, the mixture of nivolumab and ipilimumab was approved by the authority to be used in clinical practice.

Studies examination ipilimumab+nivolumab with sunitinib alone in excretory organ cell cancer and also the combination of ipilimumab+nivolumab in non-small cell respiratory organ cancer have shown favourable results [39,40]. relating to the significance of ipilimumab together medical care, future results are anticipated as as to if two-drug combos of immune stop inhibitors (ipilimumab and nivolumab combination therapy) will contribute to higher survival rates than either immune stop inhibitors alone or immune stop inhibitors in combination with therapy. Since varied aspects of the mechanism of action of ICIs in vivo ar unclear, this review discusses



Figure 2: Immune stop inhibitors in cancer treatment.

Notes: Inability to activate T cells within the growth microenvironment through the restrictive impact of Tregs or through immune checkpoints permits cancer cells to flee immune attack, survive, and grow. B7 ligands expressed on antigen-presenting cells bind to TCR and induce lymph cell amplification and reaction. instead, binding of B7 ligands to CTLA-4 expressed on T cells suppresses their activity. CTLA-4 additionally enhances the activity of Tregs resulting in immunological disorder activity. PD-1 is expressed on activated T cells. PD-1 binds to its PD-L1 leading to the energy of T cells, more promoting repressive signals.Pharmacological inhibition of immune checkpoints with being antibodies restores T cell antineoplastic activity and relieves immunological disorder. Abbreviations: CTLA-4: cytotoxic T-lymphocyte matter 4; MHC: major organic phenomenon complex; PD-1: programmed cell death-1; PD-L1: programmed cell death-1 ligand; TCR: T cell receptor; Tregs: regulative T cells; APC: matter presenting cell.

Anti-PD-1/PD-L1 antibodies act in the effector section of the cancer-immunity cycle. In the effector section, effector T cells attack cancer cells. However, binding of PD-L1 expressed on the neoplastic cell surface to PD-1 expressed on the surface of effector T cells suppresses the attack by effector T cells on cancer cells. Anti-PD-1/PD-L1 antibodies pharmacologically forestall the PD-1/PD-L1 interaction, therefore facilitating the attack by cells. what is more, these antibodies are thought to inhibit the reaction within the priming section of the cancer-immunity cycle [41]. In distinction, anti-CTLA-4 antibodies act throughout matter presentation in the priming section, whereby nerve fibre cells gift antigens to and activate T cells. T-cell activation needs each T-cell receptors (TCRs) and also the MHCI-cancer matter advanced on the nerve fibre cells (principal stimulation), accompanied by the

interaction between B7 (CD80/86) and CD28 on nerve fibre and T cells, severally (costimulation) [42]. CTLA-4, like CD28, is expressed on the lymph cell surface and binds B7 with a stronger affinity than that of CD28. Thus, once CTLA-4 is up regulated, it remains sure to B7 and also the costimulatory signal isn't transmitted, leading to the suppression of lymph cell activation [43]. Anti-CTLA-4 antibodies inhibit the binding of CTLA-4 and B7, leading to increased binding of CD28 and B7, that stimulates T-cell activation and exerts antineoplastic effects (Figure 2) [44]. what is more, CTLA-4 is gift on Treg surfaces, evoked by cancer cells, and inhibits T-cell activation by binding to B7 on nerve fibre cells [45]. Thus, anti CTLA-4 antibodies also are thought to exert antineoplastic effects by facilitating the binding of Tregs to CTLA-4 and directly eliminating Tregs.

Nanotherapy Application In Cancer

Nanomedicines like this innovative and targeted approaches to the selective treatment of cancer. With this technology, many nano-sized drug carrier systems are developed to beat biodistribution and pharmacokinetic issues of active pharmaceutical ingredients (APIs). The employment of nanoparticulate systems in cancer started in 1995 with the bureau approval of Doxil® (PEGylated liposomal doxorubicin). Then, in 1996, Doxil® was approved by the EMA beneath the name Caelyx [46]. Since then, bureau and EMA approved Nano systems have enlarged quickly. Regarding fifty five nanomedicines area unit presently employed in clinical settings and quite half them have reached the marketplace for cancer medical aid. The mixture of 2 innovative methods in cancer treatment, therapy and nanotherapy, area unit promising fields. Currently, there area unit over one hundred clinical studies victimisation mixtures of various therapy and nanocarriers. Besides the clinical studies, the mixture of atezolizumab (Tecentriq) with Abraxane was approved by the bureau to be used within the treatment of pathologic process triple negative carcinoma [47]. However, atezolizumab isn't approved to be used with Taxol (paclitaxel). This strategy is that the 1st approved example of the combined application of nanomaterials with biological medical specialty in cancer treatment. Nanoparticulate carrier systems are investigated to be used in cancer treatment {for many|for many} years with several benefits as a results of their distinctive structures listed as follows:

• Nanoparticles move directly with the plasma membrane and intracellular structures, avoiding the drug resistance mechanism by bypassing the cellular flow pump and increasing uptake into growth cells.
• Nanoparticulate systems increase the cellular uptake and accumulation of the transported medicine into the tumors.
• Nanosystems enhance the potency and stability of active molecules by protective them from biological factors like enzymes throughout blood circulation.
• The surface of Nano size carriers may be changed to active targeting or additionally targeted passively due to their particle sizes. long circulation of those nanoparticles will strengthen the targeting ability.
• Nanomedicines give increased immune responses compared to the employment of typical therapy alone. Nanoparticulate systems increase the response of the system through numerous mechanisms, i.e., by targeting specific immune cells, activating and sanctionative immune cells to acknowledge cancer cells [46]

Conclusion

Many approaches are used in clinical settings to eliminate cancer , such as chemotherapy , radiotherapy and surgery . Immunotherapy is more recent then these therapies and includes cellular therapy , antibody therapy , vaccine therapy and nonspecific therapy . Nanotechnology – based therapies have been launched as novel and more selective therapeutics for cancer treatment . for an eventual improved efficacy , nanoparticulate drug delivery system combined

immunotherapeutics are being developed both in vitro and clinically .

References

1. Global Burden of Disease Cancer Collaboration. Fitzmaurice C., Abate D., Abbasi N., Abbastabar H., Abd-Allah F., Abdel-Rahman O., Abdelalim A., Abdoli A., Abdollahpour I., et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5:1749–1768. doi: 10.1001/jamaoncol.2019.2996.

2. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654.

3. Waldman A.D., Fritz J.M., Lenardo M.J. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat. Rev. Immunol. 2020;20:651–668. doi: 10.1038/s41577-020-0306-5.

4. Oldham R.K. Cancer Biotherapy: More than Immunotherapy. Cancer Biother. Radiopharm. 2017;32:111–114. doi: 10.1089/cbr.2017.28999.old.

5. Yang Y. Cancer immunotherapy: Harnessing the immune system to battle cancer. J. Clin. Investig. 2015;125:3335–3337. doi: 10.1172/JCI83871.

6. Dine J., Gordon R., Shames Y., Kasler M.K., Barton-Burke M. Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac. J. Oncol. Nurs. 2017;4:127–135. doi: 10.4103/apjon.apjon_4_17.

7. Borghaei H., Smith M.R., Campbell K.S. Immunotherapy of cancer. Eur. J. Pharmacol. 2009;625:41–54. doi: 10.1016/j.ejphar.2009.09.067.

8. Farc O., Cristea V. An overview of the tumor microenvironment, from cells to complex networks (Review) Exp. Ther. Med. 2020;21:1. doi: 10.3892/etm.2020.9528.

9. Zhang Y., Wu L., Li Z., Zhang W., Luo F., Chu Y., Chen G. Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages. Biomacromolecules. 2018;19:2098–2108. doi: 10.1021/acs.biomac.8b00305

10. Kuai R., Yuan W., Son S., Nam J., Xu Y., Fan Y., Schwendeman A., Moon J.J. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci. Adv. 2018;4:eaao1736. doi: 10.1126/sciadv.aao1736.

11. Merino M., Contreras A., Casares N., Troconiz I.F., Hagen T.L.T., Berraondo P., Zalba S., Garrido M.J. A new immune-nanoplatform for promoting adaptive antitumor immune response. Nanomed. Nanotechnol. Biol. Med. 2019;17:13–25. doi: 10.1016/j.nano.2018.12.016.

12. Slaney C.Y., Kershaw M.H. Challenges and Opportunities for Effective Cancer Immunotherapies. Cancers. 2020;12:3164. doi: 10.3390/cancers12113164.

13. Kaplon H., Muralidharan M., Schneider Z., Reichert J.M. Antibodies to watch in 2020. MAbs. 2020;12:1703531. doi: 10.1080/19420862.2019.1703531.

14. Vaddepally R.K., Kharel P., Pandey R., Garje R., Chandra A.B. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers. 2020;12:738. doi: 10.3390/cancers12030738.

15. Wang W., Wang J., Zhang X., Wang Y., Shi J., Jia X., Dang S. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma: A cost-effectiveness analysis. J. Clin. Oncol.

2021;39:295. doi: 10.1200/JCO.2021 .39.3_suppl.295.

16. Zhao J., Chen Y., Ding Z.-Y., Liu J.-Y. Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination with Immune Checkpoint Inhibitors in Cancer Treatment. Front. Pharmacol. 2019;10:1184.

17. Quijano-Rubio A., Ulge U.Y., Walkey C.D., Silva D.-A. The advent of de novo proteins for cancer immunotherapy. Curr. Opin. Chem. Biol. 2020;56:119–128. doi: 10.1016/j.cbpa.2020.02.002.

18. Han S., Huang K., Gu Z., Wu J. Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. Nanoscale. 2020;12:413–436. doi: 10.1039/C9N R08086D]

19. Sun L., Chen L., Li H. Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms. Int Immunopharmacol. 2019;67:160–175.doi: 10.1016/j.intimp.2 018.12.006. 20.

20. Bernard-Tessier A., Bonnet C., Lavaud P., Gizzi M., Loriot Y., Massard C. Atézolizumab (Tecentriq ®): Activité, indication et modalités d'utilisation dans les carcinomes urothéliaux localement avancés ou métastatiques. Bull Cancer. 2018;105:140–145.doi: 10.1016/j.bulcan. 2017.10.03021.

21. Lu J., Liu X., Liao Y.-P., Salazar F., Sun B., Jiang W., Chang C.H., Jiang J., Wang X., Wu A., et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat. Commun. 2017;8:1–14. doi: 10.1038/s41467-017-016519.

22. Ishihara J., Ishihara A., Sasaki K., Lee S.S.-Y., Williford J.-M., Yasui M., Abe H., Potin L., Hosseinchi P., Fukunaga K., et al. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci. Transl. Med. 2019;11:eaau3259. doi: 10.1126/scit ranslmed.aau3259

23. Williford J.-M., Ishihara J., Ishihara A., Mansurov A., Hosseinchi P., Marchell T.M., Potin L., Swartz M.A., Hubbell J.A. Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Sci. Adv. 2019;5: eaay1357. doi: 10.1126/sciadv.aay1357.

24. Mansurov A., Ishihara J., Hosseinchi P., Potin L., Marchell T.M., Ishihara A., Williford J.-M., Alpar A.T., Raczy M.M., Gray L.T., et al. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat. Biomed. Eng. 2020;4:531–543. doi: 10.1038/s41551-020-0549-2]

25. Marin-Acevedo J.A., Kimbrough E.O., Lou Y. Next generation of immune checkpoint inhibitors and beyond. J. Hematol. Oncol. 2021;14:1–29. doi: 10.1186/s13045-021-01056.

26. Zahavi D., Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies. 2020;9:34. doi: 10.3390 /antib9030034.

27. Lu R.-M., Hwang Y.-C., Liu I.-J., Lee C.-C., Tsai H.-Z., Li H.-J., Wu H.-C. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 2020;27:1–30. doi: 10.1186/s12929-0 28 . Hafeez U., Parakh S., Gan H.K., Scott A.M. Antibody–Drug Conjugates for Cancer Therapy. Molecules. 2020;25 :4764. doi: 10.3390/molecules25204764

28. Chen L., Wang L., Shion H., Yu C., Yu Y.Q., Zhu L., Li M., Chen W., Gao K. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. mAbs. 2016;8:1210–1223. doi: 10.1080/194208 62.2016.1204502.

29. Gravanis I., Tzogani K., Van Hennik P., De Graeff P., Schmitt P., Mueller-Berghaus J., Salmonson T., Gisselbrecht C., Laane E., Bergmann L., et al. The

European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Oncologist. 2015;21:102–109. doi: 10.1634/theoncologist.2015-027.

30. Rohaan M.W., Wilgenhof S., Haanen J.B.A.G. Adoptive cellular therapies: The current landscape. Virchows Archiv. 2019;474:449–461. doi: 10.1007/s00428-018-2484-0

31. Zheng P.-P., Kros J.M., Li J. Approved CAR T cell therapies: Ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov. Today. 2018;23:1175–1182. doi: 10.1016/j.drudis.2018.02.012

32. Keshavarz-Fathi M., Rezaei N. Chapter 2—Immunotherapeutic Approaches in Cancer. In: Rezaei N., Keshavarz-Fathi M., editors. Vaccines for Cancer Immunotherapy. Academic Press; Cambridge, MA, USA: 2019. pp. 19–44.

33. Handy C.E., Antonarakis E.S. Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions. Future Oncol. 2018;14:907–917. doi: 10.2217/fon-2017-0531

34. Raman S.S., Hecht J.R., Chan E. Talimogene: Review of its mechanism of action and clinical efficacy and safety. Immunotherapy. 2019;11:705–723. doi: 10.2217/imt-2019-0033 laherparepvec.

35. Bommareddy P.K., Patel A., Hossain S., Kaufman H.L. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. Am. J. Clin. Dermatol. 2017;18:1–15. doi: 10.1007/s40257-016-0238-9

36. Chen, D.; Mellman, I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity 2013, 39, 1–10, doi:10.1016/j.immuni.2013.07.012.

37. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. Science 2011, 331, 1565–1570, doi:10.1126/science.1203486. Motzer, R.J.; Tannir, N.M.; McDermott, D.F.; Frontera, O.A.; Melichar, B.; Choueiri, T.K.; Plimack, E.R.; Barthelemy, P.; Porta, C.; George, S.; et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New Engl. J. Med. 2018, 378, 1277–1290, doi:10.1056/NEJMoa1712126.

38. 19-0592-z. 40 Carbone, D.P.; Reck, M.; Paz-Ares, L.; Creelan, B.; Horn, L.; Steins, M.; Felip, E.; Heuvel, M.M.V.D.; Ciuleanu, T.-E.; Badin, F.; et al. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer. New Engl. J. Med. 2017, 376, 2415–2426, doi:10.1056/NEJMoa1613493.

39. Hui, E.; Cheung, J.; Zhu, J.; Su, X.; Taylor, M.J.; Wallweber, H.A.; Sasmal, D.K.; Huang, J.; Kim, J.M.; Mellman, I.; et al. T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition. Science 2017, 355, 1428–1433, doi:10.1126/science.aaf129.

40. Sansom, D. CD28, CTLA-4 and their ligands: Who does what and to whom? Immunology 2000, 101, 169–177, doi:10.1046/j.1365-2567.2000.00121.x.

41. Rowshanravan, B.; Halliday, N.; Sansom, D. CTLA-4: A moving target in immunotherapy. Blood 2018, 131, 58–67, doi:10.1182/blood-2017-06-741033.

42. Malas, S.; Harrasser, M.; Lacy, K.E.; Karagiannis, S.N. Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review). Oncol. Rep.2014, 32, 875–86, doi:10.3892/or.2014.3275.

43. Walunas, T.L.; Lenschow, D.J.; Bakker, C.Y.; Linsley, P.S.; Freeman, G.J.; Green, J.M.; Thompson, C.B.; Bluestone, J.A. CTLA-4 can function as a negative regulator of T cell activation.

Immunity 1994, 1, 405–413, doi:10.1016/1074-7613(94)90071-x.

44. Ventola C.L. Cancer Immunotherapy, Part 1: Current Strategies and Agents. Pharm. Ther. 2017;42:375–383.

45. Shi Y. Clinical Translation of Nanomedicine and Biomaterials for Cancer Immunotherapy: Progress and Perspectives. Adv. Ther. 2020;3:1900215. doi: 10.1002/adtp.20190021.